Categories
Blood Cancer

Patients face more restrictions to consent to breast implants [Video]

The warning on breast implant packaging is a part of a series of new guidelines after women developed a type of lymphoma.

ST. PETERSBURG, Fla. — The Food and Drug Administration is putting a new black box warning on the packaging for breast implants. This new guidance is part of a series of recommendations from an advisory panel that met back in 2019

Here are the changes the FDA is putting in place:

  • Restricting the sale and distribution of breast implants and only allowing health care providers who use their Patient Decision Checklist to be able to purchase them. Patients are required to sign it, acknowledging the risks of getting implants.
  • Updating guidelines for screening women who have silicone implants to make sure their implants don't rupture.
  • Manufacturers must update their websites with new information on the labeling in the next 30 days.

More than 730 patients have reported a problem to the FDA. According to the American Society of Plastic Surgeons

Watch/Read More
Categories
Blood Cancer Breast Cancer Prostate Cancer Skin Cancer

Study to examine massage benefits for cancer patients [Video]

Clinical trials have begun to explore the benefits that therapeutic massage can provide in alleviating some of the most debilitating symptoms of breast cancer.

Categories
Blood Cancer

CAR-T in multiple myeloma: cilta-cel & ide-cel [Video]

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, shares his thoughts on how the addition of ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) to the treatment paradigm is adding value to the treatment of patients with multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

Initial Safety Results for Phase 2 MagnetisMM-3 Trial Presented at ASCO 2022 [Video]

Dr. Alexander M. Lesokhin (Memorial Sloan Kettering Cancer Center—New York, NY) discusses initial safety results for MagnetisMM-3: Phase 2 Trial of elranatamab (BCMA)-CD3 bispecific antibody in RRMM patients. What is the purpose of this trial? MagnetisMM-3 is an open-label, multicenter, non-randomized, phase 2 study to evaluate the safety and efficacy of elranatamab monotherapy in relapsed/refractory multiple myeloma (RRMM) patients. Initial safety results are presented. The purpose of the study is to evaluate whether single-agent elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and B cell maturation antigen (BCMA)-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity. Conclusion: Preliminary results of MagnetisMM-3 in RRMM patients with no prior BCMA-targeted treatment suggest that 76 mg QW elranatamab with a 2-step-up priming regimen is well tolerated, with no Grade ≥3 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) observed. Clinical trial information: NCT04649359 Doctor Bio: Dr. Alexander M. Lesokhin is a Hematologic Oncologist at Memorial Sloan Kettering Cancer Center in New York, NY. His clinical expertise is in multiple myeloma and immunotherapy. _______________Improving Lives | Finding the CureIn the United States, an estimated 32,270 new multiple myeloma cases will be diagnosed in 2021. 159,985 new myeloma cases are diagnosed yearly. Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.Subscribe to our channel: https://www.youtube.com/c/IMFMyelomaVisit our website at: https://www.myeloma.orgFind us online:Facebook: @myeloma | https://facebook.com/myelomaTwitter: @IMFMyeloma | https://twitter.com/IMFmyelomaInstagram: @imfmyeloma | https://www.instagram.com/imfmyelomaLinkedIn: https://www.linkedin.com/company/international-myeloma-foundationSupport the IMF! http://bit.ly/WskQHCCategoryNonprofits & ActivismLicenseStandard YouTube LicenseIn most cases, captions are autogenerated by YouTube.